Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat with TPF for SMARCB1-Deficient Sinonasal Carcinoma
NCT05151588Phase 2Not yet recruiting
- Start
- Sep 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of tazemetostat in sinonasal carcinoma. Primary endpoints: Best Objective Response at 48 months and R0 Resection Rate at 48 months. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
tazemetostat
03
Conditions
sinonasal carcinoma
Beyond the preview
Go deeper on NCT05151588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05151588.